Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Hepatoblastoma × sintilimab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 21 Stomach Neoplasms 17 Carcinoma, Non-Small-Cell Lung 12 Colorectal Neoplasms 8 Nasopharyngeal Carcinoma 5 Lung Neoplasms 5 Esophageal Squamous Cell Carcinoma 4 Squamous Cell Carcinoma of Head and Neck 3 Neoplasms 3 Lymphoma, Extranodal NK-T-Cell 3 Cholangiocarcinoma 3 Small Cell Lung Carcinoma 2 Nonsquamous Non-Small Cell Lung Cancer 2 Liver Neoplasms 2 Carcinoma, Renal Cell 2 Carcinoma, Neuroendocrine 2 Carcinoma 2 Advanced Biliary Tract Cancer 2 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Thoracic Neoplasms 1 Thoracic Malignancies 1 Small Cell Lung Cancer Extensive Stage 1 Sarcoma 1 Respiratory Tract Diseases 1 Recurrent/ Advanced Stage Endometrial Cancer Patients 1 Rectal Neoplasms 1 Precancerous Conditions 1 Pancreatic Neoplasms 1 PD-1 Antibody 1

Interventions

sintilimab 1 pembrolizumab 1 lenvatinib 1 camrelizumab 1 Vorinostat 1 Sugammadex 1 Neoadjuvant Therapy 1 Irinotecan 1 Immune Checkpoint Inhibitors 1 Granulocyte-Macrophage Colony-Stimulating Factor 1 Granulocyte Colony-Stimulating Factor 1 Drug Therapy 1 Doxorubicin 1 Cyclophosphamide 1 Cisplatin 1 Chemotherapy, Adjuvant 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05322187 2022-04-11

sPLENTY-pc

RenJi Hospital

Phase 2/3 Unknown

Gastrointestinal

Liver Neoplasms, Neoplasms, Hepatoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡